Key Points
- Pharvaris President Peng Lu sold 15,000 shares for approximately $601,950, reducing his direct stake by 18.71%. The sale was made to cover tax-withholding obligations tied to vested equity awards.
- Pharvaris reported a quarterly loss of $0.81 per share, missing the $0.75 consensus estimate. The stock opened at $38.06, with a market capitalization of about $2.49 billion.
- Investor sentiment remains mixed but generally positive: phase III data showed once-daily deucrictibant reduced hereditary angioedema attacks by 83%, while analysts maintain a “Moderate Buy” consensus and an average price target near $59.87.
Pharvaris N.V. (NASDAQ:PHVS - Get Free Report) CEO Berndt Modig sold 2,291 shares of the business's stock in a transaction dated Monday, September 14th. The stock was sold at an average price of $39.40, for a total value of $90,265.40. Following the transaction, the chief executive officer directly owned 128,334 shares of the company's stock, valued at $5,056,359.60. This represents a 1.75% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
Berndt Modig also recently made the following trade(s):
- On Friday, August 14th, Berndt Modig sold 2,292 shares of Pharvaris stock. The shares were sold at an average price of $34.77, for a total value of $79,692.84.
Pharvaris Stock Down 2.1%
PHVS opened at $38.06 on Wednesday. The firm has a market capitalization of $2.49 billion, a P/E ratio of -12.48 and a beta of -2.33. The stock's 50 day moving average price is $35.27 and its two-hundred day moving average price is $31.56. Pharvaris N.V. has a 12-month low of $20.65 and a 12-month high of $43.25.
Pharvaris (NASDAQ:PHVS - Get Free Report) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.81) EPS for the quarter, missing the consensus estimate of ($0.75) by ($0.06). As a group, analysts anticipate that Pharvaris N.V. will post -3.12 earnings per share for the current year.
Pharvaris News Summary
Here are the key news stories impacting Pharvaris this week:
- Positive Sentiment: Pharvaris’ phase III data showed that once-daily extended-release deucrictibant reduced hereditary angioedema (HAE) attacks by 83%. The results support the company’s plans to pursue regulatory submissions in 2027 and strengthen the investment case for its lead drug candidate. PHVS Stock Rises 10% in a Month: What Is Driving the Rally?
- Positive Sentiment: Analyst expectations have improved, with the consensus price target reportedly raised 20.08% to $59.77. Recent coverage also includes RBC raising its target to $62 and maintaining an outperform rating, while the broader analyst consensus remains “Moderate Buy.” Pharvaris NV consensus price target raised 20.08% to $59.77
- Positive Sentiment: Recent institutional buying—including new positions from BlackRock and increased holdings by Alyeska Investment Group and Seven Fleet Capital—signals growing professional-investor interest in PHVS.
- Neutral Sentiment: Pharvaris presented at the Morgan Stanley 24th Annual Global Healthcare Conference, giving management another opportunity to discuss deucrictibant and the company’s development and regulatory strategy with institutional investors. The supplied transcript headline does not identify a separate new announcement. Pharvaris Presents at Morgan Stanley Global Healthcare Conference
- Negative Sentiment: Insider selling is a counterweight: CEO Berndt Modig sold 2,291 shares, President Peng Lu sold 15,000 shares, and insider Anne Lesage sold 30,000 shares for approximately $1.15 million. Lu’s sale was specifically described as covering tax withholding tied to vested equity, which reduces—but does not eliminate—the negative signal. Insider Selling: Pharvaris Insider Sells 30,000 Shares
Analyst Upgrades and Downgrades
PHVS has been the topic of a number of research reports. Citigroup reaffirmed a "market outperform" rating on shares of Pharvaris in a research report on Wednesday, September 9th. New Street Research set a $60.00 price target on shares of Pharvaris in a report on Friday, August 14th. UBS Group set a $79.00 price objective on shares of Pharvaris in a report on Wednesday, September 9th. Wells Fargo & Company upped their price objective on shares of Pharvaris from $55.00 to $65.00 and gave the company an "overweight" rating in a research report on Wednesday, September 9th. Finally, Leerink Partners upped their price objective on shares of Pharvaris from $50.00 to $65.00 and gave the company an "outperform" rating in a research report on Wednesday, September 9th. Thirteen research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $59.87.
Read Our Latest Report on PHVS
Institutional Inflows and Outflows
A number of large investors have recently modified their holdings of the company. venBio Partners LLC acquired a new position in shares of Pharvaris in the 2nd quarter valued at $160,569,809. Wellington Management Group LLP raised its position in Pharvaris by 12.9% in the second quarter. Wellington Management Group LLP now owns 2,392,934 shares of the company's stock worth $82,748,000 after purchasing an additional 274,034 shares in the last quarter. Commodore Capital LP lifted its stake in Pharvaris by 1.6% during the first quarter. Commodore Capital LP now owns 1,918,970 shares of the company's stock worth $54,211,000 after purchasing an additional 29,525 shares during the period. 5AM Venture Management LLC bought a new position in Pharvaris during the second quarter worth about $27,581,008. Finally, Seven Fleet Capital Management LP boosted its holdings in Pharvaris by 144.6% during the second quarter. Seven Fleet Capital Management LP now owns 774,501 shares of the company's stock valued at $26,782,000 after purchasing an additional 457,804 shares in the last quarter.
Pharvaris Company Profile
(
Get Free Report)
Pharvaris N.V. is a biopharmaceutical company focused on developing oral therapies for hereditary angioedema (HAE), a rare genetic disorder characterized by recurrent episodes of swelling. The company is headquartered in Zug, Switzerland, and was founded in 2015 by former executives from Pharming Group.
Pharvaris' lead investigational medicine is deucrictibant, an orally administered small-molecule bradykinin B2 receptor antagonist. The company is evaluating different formulations of deucrictibant for both on-demand treatment of HAE attacks and long-term prevention of attacks.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
